title: [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
abstract: In the past few years, pathogen reduction technologies for labile blood products have been part of the enhancement of global transfusion safety regarding residual risks of transmitting infectious pathogens. Having carried out a feasibility study for the implementation of pathogen inactivation of platelet concentrates by means of the amotosalen/HCl/UVA (Intercept™) technology, and participated to a reinforced haemovigilance study, we took the opportunity to analyze the organization consequences for platelet concentrates inventory and distribution. This impact study first indicated that those novel needs forced the blood donation service, as well as the labile blood product preparation laboratory, to review and improve practices; secondly, it showed that the routine implementation has little (no major) consequence in the overall organization, independently of the economic consequences (not covered here).
authors.affiliation: Établissement français du sang Auvergne-Loire, Saint-Étienne, France. patricia.chavarin@efs.sante.fr
authors.forename: P
authors.initials: P
authors.lastname: Chavarin
authors.forename: C
authors.initials: C
authors.lastname: DePutter
authors.forename: F
authors.initials: F
authors.lastname: Boussoulade
authors.forename: S
authors.initials: S
authors.lastname: Acquart
authors.forename: M
authors.initials: M
authors.lastname: Vidal
authors.forename: C
authors.initials: C
authors.lastname: Argaud
authors.forename: P
authors.initials: P
authors.lastname: Fabrigli
authors.forename: O
authors.initials: O
authors.lastname: Garraud
mesh_terms: D017848:Blood-Borne Pathogens; D006801:Humans; D017053:Infection Control / Q000379:methods* / Q000458:organization & administration; D017713:Platelet Transfusion / Q000009:adverse effects*